SCHEMBL8050872

SCHEMBL8050872

Cc1cc(C)nc(N2CCC(C(C)(C)S(=O)(=O)c3cccc(C(F)(F)F)c3)CC2)n1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.55
MEN1 O00255 2/20 0.55
ALDH1A1 P00352 1/20 0.55
TSHR P16473 2/20 0.52
CYP3A4 P08684 2/20 0.52
CACNA1B Q00975 2/20 0.52
NR1I2 O75469 1/20 0.52
USP2 O75604 3/20 0.45
KDM4E B2RXH2 2/20 0.45
HTT P42858 2/20 0.45
HSD17B10 Q99714 2/20 0.45
LMNA P02545 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
CTSS P25774 1/20 0.42
IDH2 P48735 3/20 0.42
PKM P14618 1/20 0.41
HTR6 P50406 1/20 0.41
RBP4 P02753 1/20 0.41
HPGD P15428 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL3034909 0.94 KMT2A (0.55) KMT2AMEN1ALDH1A1TSHRCYP3A4
SCHEMBL15108576 0.81 CACNA1B (0.60) ALDH1A1CYP3A4CACNA1BNR1I2HTT
SCHEMBL3032201 0.80 GPR119 (0.54) KMT2AMEN1ALDH1A1CYP3A4CACNA1B
SCHEMBL3043349 0.79 CYP3A4 (0.44) KMT2AMEN1ALDH1A1TSHRCYP3A4
SCHEMBL8043819 0.79 SLC40A1 (0.49) TSHRCYP3A4CACNA1BNR1I2USP2
SCHEMBL3042305 0.79 CYP3A4 (0.49) KMT2AMEN1ALDH1A1CYP3A4CACNA1B
SCHEMBL3025290 0.79 CACNA1B (0.51) KMT2AMEN1CYP3A4CACNA1BNR1I2
SCHEMBL3025631 0.79 TRPV1 (0.52) ALDH1A1CYP3A4CACNA1BNR1I2KDM4E
SCHEMBL3038156 0.79 MEN1 (0.49) KMT2AMEN1CYP3A4CACNA1BNR1I2
SCHEMBL3038435 0.78 CACNA1B (0.57) KMT2ATSHRCYP3A4CACNA1BNR1I2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2205083-B1 Substituted aryl sulfone derivatives as calcium channel blockers MERCK SHARP & DOHME (US) 2013-07-17 EP claimed
US-20130040932-A1 SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS NEUROMED PHARMACEUTICALS LTD. (CA) 2013-02-14 US disclosed
US-20130040932-A1 SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS NEUROMED PHARMACEUTICALS LTD. (CA) 2013-02-14 US disclosed
US-8304434-B2 Substituted aryl sulfone derivatives as calcium channel blockers MERCK SHARP & DOHME CORP. (US) 2012-11-06 US disclosed
US-20100210620-A1 Substituted Aryl Sulfone Derivatives as Calcium Channel Blockers SCHERING CORPORATION 2010-08-19 US disclosed
WO-2009045382-A1 SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS MERCK & CO., INC. (US) 2009-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100210620-A1 Substituted Aryl Sulfone Derivatives as Calcium Channel Blockers TRPV1, TRPA1, CACNA1D KMT2A 2427/4885MEN1 3564/4885ALDH1A1 489/4885
US-20130040932-A1 SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS TRPV1, TRPA1, CACNA1D KMT2A 2427/4885MEN1 3564/4885ALDH1A1 489/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.